Search

Your search keyword '"Fusco N"' showing total 17 results
Start Over Author "Fusco N" Publisher springer science and business media llc
17 results on '"Fusco N"'

16. A sharp stability result for the Gauss mean value formula

Author

Giovanni Cupini, Xiao Zhong, Nicola Fusco, Ermanno Lanconelli, Cupini, G., Lanconelli, E., Fusco, N., Zhong, X., Cupini G., Lanconelli E., Fusco N., and Zhong X.

Subjects
Partial differential equation, Gauss mean value theorem, stability, harmonic functions, Harmonic function, Quantitative stability, General Mathematics, Mean value, Gauss, Applied mathematics, Stability result, Stability (probability), Analysis, Mathematics
Abstract

We prove a quantitative stability result for the Gauss mean value formula. We also show by an example that the estimate proved here is sharp.

Published
2020

17. CXCL12 expression is a bona fide predictor of recurrence in lung neuroendocrine tumours; a multicentric study with emphasis on atypical carcinoids - a short report

Author

Fabio Pagni, Alessandro Del Gobbo, Caterina Marchiò, Nicola Fusco, Amedeo Sciarra, Alessandro Palleschi, Marco Barella, Stefano Ferrero, Giulia Ercoli, Mauro Papotti, Del Gobbo, A, Fusco, N, Barella, M, Ercoli, G, Sciarra, A, Palleschi, A, Pagni, F, Marchiò, C, Papotti, M, and Ferrero, S

Subjects
Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Lung neuroendocrine tumours, Lung Neoplasms, Prognostic biomarker, medicine.medical_treatment, Lung neuroendocrine tumour, Carcinoid Tumor, Neuroendocrine tumors, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Lung cancer, Aged, Heterogeneous group, Lung, business.industry, Carcinoids, General Medicine, Middle Aged, CXCL12, medicine.disease, Carcinoid, Molecular medicine, Chemokine CXCL12, Neuroendocrine Carcinomas, Neuroendocrine Tumors, Prognostic biomarkers, Molecular Medicine, 030104 developmental biology, medicine.anatomical_structure, Cytokine, 030220 oncology & carcinogenesis, Immunohistochemistry, Female, Neoplasm Recurrence, Local, business
Abstract

Purpose: Neuroendocrine tumors of the lung (LNETs) encompass a heterogeneous group of lesions, including tumors with no or low metastatic potential, such as typical (TCs) and atypical (ACs) carcinoids, and highly aggressive neuroendocrine carcinomas. To date, only a few biomarkers with prognostic impact have been identified in LNETs. Previous experimental studies have suggested that the cytokine CXCL12 might have a role in stratifying the outcome of lung cancer as well as LNET patients. However, the reliability of immunohistochemical (IHC) tissue expression of CXCL12 in evaluating the prognosis of resected LNETs is currently not known. Methods: Here, we subjected a cohort of 112 resected LNETs specifically enriched for ACs to IHC for CXCL12 and Ki67 using routine procedures. The clinical value of CXCL12 was assessed by applying the Cox proportional-hazards model to overall and disease-free survival rates. Results: We found that CXCL12 was expressed in 8.3 to 38% of LNETs, depending on the different diagnostic categories. Upon survival analysis, when considering the whole cohort, we found that CXCL12-positive cases exhibited shorter disease-free survival rates compared to CXCL12-negative cases. Among ACs, tumors overexpressing CXCL12 showed significantly shorter disease-free survival rates. Finally, we found that the Ki67 index in ACs was higher in the CXCL12-positive cases. Conclusion: CXCL12 immunohistochemistry may serve as a potentially useful tool to better stratify LNETs, and more specifically ACs, in clinical practice.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results